This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
health care | 188 |
coronavirus disease | 86 |
public health | 78 |
care workers | 78 |
mental health | 64 |
acute respiratory | 61 |
respiratory syndrome | 56 |
severe acute | 54 |
united states | 48 |
convalescent plasma | 41 |
healthcare workers | 41 |
ann intern | 40 |
intern med | 40 |
cord uid | 38 |
doc id | 38 |
med doi | 38 |
influenza pandemic | 37 |
health literacy | 34 |
novel coronavirus | 31 |
converting enzyme | 31 |
syndrome coronavirus | 27 |
positive persons | 24 |
arb use | 24 |
intensive care | 24 |
risk factors | 22 |
cohort study | 22 |
primary care | 22 |
hospitalized patients | 22 |
posted online | 22 |
systematic review | 21 |
care system | 20 |
internal medicine | 20 |
hydroxychloroquine alone | 20 |
preprint posted | 19 |
among health | 18 |
severe covid | 17 |
comorbid conditions | 17 |
clinical trials | 17 |
tdf ftc | 17 |
persons receiving | 16 |
angiotensin ii | 16 |
receptor blockers | 16 |
standard treatment | 16 |
new york | 15 |
enzyme inhibitors | 15 |
homeless shelters | 15 |
chain reaction | 15 |
african american | 15 |
influenza vaccine | 15 |
participant encounters | 15 |
american college | 15 |
black americans | 14 |
receiving art | 14 |
medical staff | 14 |
ccf expo | 14 |
world health | 14 |
polymerase chain | 14 |
health outcomes | 14 |
national institutes | 14 |
certainty evidence | 13 |
clinical trial | 13 |
social distancing | 13 |
surge testing | 13 |
case series | 13 |
chronic conditions | 13 |
practice points | 13 |
respiratory viruses | 13 |
routine surveillance | 13 |
health disparities | 13 |
emergency use | 13 |
observational studies | 13 |
current author | 12 |
author addresses | 12 |
pulmonary embolism | 12 |
low health | 12 |
minority communities | 12 |
infectious disease | 12 |
personal protective | 12 |
will get | 12 |
patients hospitalized | 12 |
general population | 12 |
decision making | 12 |
health support | 12 |
clinician mental | 12 |
general hospital | 12 |
psychological impact | 12 |
randomized clinical | 12 |
test results | 12 |
patients receiving | 12 |
health organization | 12 |
controlled trial | 11 |
moral injury | 11 |
african americans | 11 |
use authorization | 11 |
positive sars | 11 |
clinical outcomes | 11 |
poverty level | 11 |
systematic reviews | 11 |
among patients | 11 |
clinician well | 11 |
health equity | 11 |
protective equipment | 11 |
care unit | 10 |
york city | 10 |
treating covid | 10 |
influenza vaccination | 10 |
diffuse alveolar | 10 |
heart failure | 10 |
clinical characteristics | 10 |
among hiv | 10 |
alone compared | 10 |
vaccine hesitancy | 10 |
versus yes | 10 |
high risk | 10 |
antibody responses | 10 |
alveolar damage | 9 |
racial disparities | 9 |
actions related | 9 |
occupational health | 9 |
icu admission | 9 |
evidence review | 9 |
infectious diseases | 9 |
critical revision | 9 |
evidence synthesis | 9 |
confirmed covid | 9 |
randomized controlled | 9 |
important intellectual | 9 |
org annals | 9 |
intellectual content | 9 |
older adults | 9 |
patient care | 9 |
sectional study | 9 |
respiratory tract | 9 |
receiving tdf | 9 |
serologic assays | 9 |
may also | 9 |
positive patients | 9 |
coronavirus infection | 9 |
posttraumatic stress | 8 |
living systematic | 8 |
illness severity | 8 |
federal government | 8 |
observational study | 8 |
reverse transcriptase | 8 |
psychological distress | 8 |
like illness | 8 |
narrative review | 8 |
computed tomography | 8 |
severe illness | 8 |
healthcare personnel | 8 |
infection among | 8 |
angiotensin receptor | 8 |
org authors | 8 |
factors associated | 8 |
cohort studies | 8 |
health system | 8 |
among healthcare | 8 |
among african | 8 |
social support | 8 |
authors icmje | 8 |
coronavirus pandemic | 7 |
aged years | 7 |
foreign workers | 7 |
vital signs | 7 |
lower health | 7 |
disease control | 7 |
age distribution | 7 |
based isolation | 7 |
positive results | 7 |
prospective cohort | 7 |
virus infection | 7 |
previous pandemics | 7 |
sars outbreak | 7 |
severe disease | 7 |
practice implications | 7 |
viral infections | 7 |
across studies | 7 |
angiotensin system | 7 |
sars cov | 7 |
update alert | 7 |
health workers | 7 |
participant characteristics | 7 |
randomized trials | 7 |
arbs may | 7 |
frontline healthcare | 7 |
submitted work | 7 |
lower risk | 7 |
becomes available | 7 |
black race | 7 |
health conditions | 7 |
health status | 7 |
clinical features | 7 |
health crisis | 7 |
respiratory virus | 7 |
venous thromboembolism | 7 |
hospital admission | 7 |
educational attainment | 7 |
among frontline | 7 |
treatment guidelines | 7 |
institutional review | 6 |
social determinants | 6 |
respiratory distress | 6 |
middle east | 6 |
race ethnicity | 6 |
mortality rate | 6 |
medical consultation | 6 |
health systems | 6 |
medical school | 6 |
viral rna | 6 |
icmje conflictofinterestforms | 6 |
positive cases | 6 |
potential sars | 6 |
test result | 6 |
heart disease | 6 |
taf ftc | 6 |
vaccination rates | 6 |
medical education | 6 |
national survey | 6 |
ill patients | 6 |
ethnic minority | 6 |
enzyme inhibitor | 6 |
original research | 6 |
daily routine | 6 |
one third | 6 |
testing events | 6 |
funding source | 6 |
plasma therapy | 6 |
think i | 6 |
basic needs | 6 |
case fatality | 6 |
hand hygiene | 6 |
nursing homes | 6 |
critically ill | 6 |
correctional officers | 6 |
study staff | 6 |
cardiovascular disease | 6 |
serologic studies | 6 |
consultation rooms | 6 |
appendix table | 6 |
drug administration | 6 |
author contributions | 6 |
mitigation strategies | 6 |
logistic support | 6 |
outcomes among | 6 |
attitudes toward | 6 |
care personnel | 6 |
randomized trial | 6 |
primary funding | 6 |
infection control | 6 |
isolation facilities | 6 |
care providers | 6 |
global health | 6 |
increased risk | 6 |
i will | 6 |
review board | 6 |
incarcerated persons | 6 |
new coronavirus | 6 |
disease course | 6 |
transmission dynamics | 6 |
among persons | 6 |
east respiratory | 6 |
viral replication | 6 |
positivity rate | 5 |
unique participants | 5 |
psychological well | 5 |
lateral flow | 5 |
care facilities | 5 |
ari symptoms | 5 |
clinical policy | 5 |
sex differences | 5 |
evidence ecosystem | 5 |
functional receptor | 5 |
clinical course | 5 |
first responders | 5 |
upper respiratory | 5 |
distress syndrome | 5 |
antiretroviral therapy | 5 |
vaccine development | 5 |
age structure | 5 |
nonmedical health | 5 |
retrospective study | 5 |
pulmonary disease | 5 |
seroepidemiologic studies | 5 |
antibody titers | 5 |
serologic tests | 5 |
reports grants | 5 |
correctional staff | 5 |
several countries | 5 |
human coronaviruses | 5 |
electronic health | 5 |
health interventions | 5 |
flu vaccine | 5 |
symptomatic patients | 5 |
social isolation | 5 |
health covid | 5 |
sars patients | 5 |
vaccine among | 5 |
future public | 5 |
two thirds | 5 |
child care | 5 |
peer support | 5 |
mortality among | 5 |
patient died | 5 |
life expectancy | 5 |
health services | 5 |
palliative care | 5 |
cycle threshold | 5 |
adverse effects | 5 |
care worker | 5 |
disease severity | 5 |
influenza transmission | 5 |
workers exposed | 5 |
nasal swab | 5 |
expanded access | 5 |
pilot study | 5 |
available evidence | 5 |
hospital workers | 5 |
health response | 5 |
essential workers | 5 |
time must | 5 |
among symptomatic | 5 |
ii receptor | 5 |
arb therapy | 5 |
socioeconomic status | 5 |
sectional survey | 5 |
sars coronavirus | 5 |
fatality rate | 5 |
providing care | 5 |
immune response | 5 |
one half | 5 |
venous thrombosis | 5 |
patient characteristics | 5 |
higher risk | 5 |
lung sections | 5 |
personal risk | 5 |
household income | 5 |
supplement table | 5 |
angiotensinconverting enzyme | 5 |
related coronavirus | 5 |
sick leave | 5 |
antibody test | 5 |
viral load | 5 |
infection fatality | 5 |
transcriptase polymerase | 5 |
distancing mandates | 5 |
graduate medical | 5 |
logistic regression | 5 |
evs workers | 5 |
deep venous | 5 |
vital sign | 5 |
titer plasma | 5 |
historical insights | 5 |
research assay | 5 |
disease burden | 5 |
mild symptoms | 4 |
statistically significant | 4 |
moderate covid | 4 |
cytokine levels | 4 |
new evidence | 4 |
eua products | 4 |
historical arc | 4 |
i think | 4 |
asymptomatic sars | 4 |
support programs | 4 |
mask use | 4 |
ct values | 4 |
disease outbreak | 4 |
medical consults | 4 |
mass index | 4 |
higher among | 4 |
patients treated | 4 |
multivariable analyses | 4 |
control group | 4 |
regression models | 4 |
deaths among | 4 |
personal fees | 4 |
provide insight | 4 |
quarantine facility | 4 |
staff members | 4 |
mortality rates | 4 |
fatality ratio | 4 |
results among | 4 |
university hospital | 4 |
health insurance | 4 |
nursing home | 4 |
antibody tests | 4 |
search strategy | 4 |
managing covid | 4 |
shelter hospitals | 4 |
nasopharyngeal swab | 4 |
series study | 4 |
shelter residents | 4 |
general public | 4 |
underlying conditions | 4 |
social connection | 4 |
abc tc | 4 |
inflammatory syndrome | 4 |
reference standard | 4 |
policy staff | 4 |
achieve herd | 4 |
angiotensin converting | 4 |
specimens collected | 4 |
year group | 4 |
control measures | 4 |
virus infections | 4 |
study using | 4 |
body mass | 4 |
coronavirus pneumonia | 4 |
prior receipt | 4 |
stress reduction | 4 |
stress disorder | 4 |
care access | 4 |
system inhibitors | 4 |
study participation | 4 |
correctional workers | 4 |
health record | 4 |
substantially lower | 4 |
sure versus | 4 |
many health | 4 |
higher likelihood | 4 |
patients may | 4 |
cluster randomised | 4 |
data collection | 4 |
rate among | 4 |
essential role | 4 |
included patients | 4 |
antibody detection | 4 |
clear communication | 4 |
teaching hospital | 4 |
cytokine storm | 4 |
chronic obstructive | 4 |
clinician wellness | 4 |
antivaccine attitudes | 4 |
health professionals | 4 |
professional societies | 4 |
tomography scan | 4 |
vaccine uptake | 4 |
receptor blocker | 4 |
ethnic disparities | 4 |
confounding factors | 4 |
respiratory symptoms | 4 |
life support | 4 |
evs staff | 4 |
obstructive pulmonary | 4 |
nab titers | 4 |
epidemiological characteristics | 4 |
neutralizing antibodies | 4 |
epidemic disease | 4 |
burden estimates | 4 |
isolation quarantine | 4 |
representative sample | 4 |
inflammatory cytokines | 4 |
multisystem inflammatory | 4 |
relative risk | 4 |
underlying health | 4 |
including sars | 4 |
guidelines panel | 4 |
community isolation | 4 |
cause mortality | 4 |
study period | 4 |
jim crow | 4 |
hiv infection | 4 |
key question | 4 |
studies included | 4 |
patients without | 4 |
homeless populations | 4 |
vaccine candidates | 4 |
nrti regimen | 4 |
national center | 4 |
autopsy findings | 4 |
best practices | 4 |
respir viruses | 4 |
serologic surveillance | 4 |
washington state | 4 |
study date | 4 |
environmental services | 4 |
psychological support | 4 |
low risk | 4 |
cluster randomized | 4 |
prevent infection | 4 |
older populations | 4 |
spanish flu | 4 |
clinical efficacy | 4 |
overall health | 4 |
mainland china | 4 |
pandemic presents | 4 |
infected persons | 4 |
control study | 4 |
sex distribution | 4 |
angiotensinaldosterone system | 4 |
symptomatic covid | 4 |
systemic lupus | 4 |
active surveillance | 4 |
received plasma | 4 |
pandemic response | 4 |
herd immunity | 4 |
sleeping arrangements | 4 |
among encounters | 4 |
high levels | 4 |
northwestern university | 4 |
data show | 4 |
care resources | 4 |
mayo clinic | 4 |
higher case | 4 |
confirmed cases | 4 |
results may | 4 |
white adults | 4 |
available data | 4 |
care professionals | 4 |
disparate health | 4 |
lupus erythematosus | 4 |
several factors | 4 |
vulnerable populations | 4 |
medical care | 4 |
fangcang shelter | 4 |
less likely | 4 |
will need | 4 |
serologic assay | 4 |
protective immunity | 4 |
younger populations | 4 |
specific antibody | 4 |
within days | 4 |
retrospective cohort | 4 |
medical schools | 4 |
medical masks | 4 |
symptom duration | 4 |
death rate | 4 |
independently associated | 4 |
racial differences | 4 |
baltimore afro | 4 |
powered rcts | 4 |
nationwide outbreak | 4 |
findings suggest | 4 |
help us | 3 |
studies found | 3 |
devices emergency | 3 |
died weeks | 3 |
poisson regression | 3 |
quality assessment | 3 |
laboratory results | 3 |
environmental cleaning | 3 |
health administration | 3 |
qtc interval | 3 |
positivity rates | 3 |
accept vaccination | 3 |
inflammatory process | 3 |
epidemiologic data | 3 |
asking participants | 3 |
endemic coronaviruses | 3 |
eap data | 3 |
treatment interventions | 3 |
physician well | 3 |
taste dysfunction | 3 |
health structures | 3 |
china medical | 3 |
total loss | 3 |
rates among | 3 |
new meta | 3 |
psychological costs | 3 |
nosocomial transmission | 3 |
critical information | 3 |
survey conducted | 3 |
preventive health | 3 |
gender differences | 3 |
date information | 3 |
saphenous vein | 3 |
coronavirus i | 3 |
care facility | 3 |
government response | 3 |
substantially different | 3 |
preexisting conditions | 3 |
antibody testing | 3 |
graduating students | 3 |
community leaders | 3 |
mediated immunity | 3 |
pandemic date | 3 |
national institute | 3 |
without covid | 3 |
across several | 3 |
deceased patients | 3 |
lung weight | 3 |
laboratory markers | 3 |
tenofovir alafenamide | 3 |
restorative justice | 3 |
randomised trial | 3 |
evidence supporting | 3 |
synthesis group | 3 |
asymptomatic persons | 3 |
improve patient | 3 |
respiratory syncytial | 3 |
diabetes mellitus | 3 |
glass opacities | 3 |
molecular docking | 3 |
literature surveillance | 3 |
findings highlight | 3 |
treatment expert | 3 |
case study | 3 |
health activation | 3 |
noninstitutionalized persons | 3 |
test performance | 3 |
racial health | 3 |
case detection | 3 |
animal models | 3 |
complex drug | 3 |
points based | 3 |
estimated effect | 3 |
otolaryngologic symptoms | 3 |
feinberg school | 3 |
living mapping | 3 |
limited health | 3 |
ongoing surveillance | 3 |
called community | 3 |
study showed | 3 |
oxygen requirement | 3 |
routine respiratory | 3 |
found high | 3 |
homeless adults | 3 |
community care | 3 |
resource library | 3 |
medical workers | 3 |
ebola virus | 3 |
study covid | 3 |
true effect | 3 |
collected data | 3 |
receiving taf | 3 |
among adults | 3 |
death among | 3 |
rheumatic diseases | 3 |
study found | 3 |
vaccination coverage | 3 |
vaccination among | 3 |
medical center | 3 |
medical comorbid | 3 |
common comorbid | 3 |
surprising ways | 3 |
carlos iii | 3 |
increased likelihood | 3 |
close contact | 3 |
resilience approach | 3 |
critical care | 3 |
disease outbreaks | 3 |
response options | 3 |
table provides | 3 |
shelter staff | 3 |
vaccine skepticism | 3 |
independently coded | 3 |
symptom onset | 3 |
syncytial virus | 3 |
surveillance sites | 3 |
experience team | 3 |
care among | 3 |
ground glass | 3 |
organ weights | 3 |
seriously ill | 3 |
systematic evidence | 3 |
currently available | 3 |
population density | 3 |
online hydroxychloroquine | 3 |
future research | 3 |
viral shedding | 3 |
post hoc | 3 |
health communication | 3 |
descriptive statistics | 3 |
based surveillance | 3 |
following page | 3 |
nervous system | 3 |
time rt | 3 |
baseline characteristics | 3 |
household size | 3 |
viral infection | 3 |
work hours | 3 |
ifr estimates | 3 |
detection tests | 3 |
drug regimens | 3 |
dimer levels | 3 |
high incidence | 3 |
historically contributed | 3 |
prior research | 3 |
cochrane database | 3 |
imperfect sensitivity | 3 |
evidence generation | 3 |
hospital setting | 3 |
clear messages | 3 |
preventing influenza | 3 |
lower educational | 3 |
recent report | 3 |
short term | 3 |
expert group | 3 |
virtual autopsy | 3 |
young adults | 3 |
hispanic persons | 3 |
united kingdom | 3 |
recent study | 3 |
perceived concern | 3 |
molecular testing | 3 |
country variation | 3 |
age group | 3 |
newly arrived | 3 |
additional information | 3 |
known harms | 3 |
adequate rest | 3 |
health emergency | 3 |
remains uncertain | 3 |
characteristics associated | 3 |
positive result | 3 |
patients showed | 3 |
broader scholarship | 3 |
case report | 3 |
postmortem computed | 3 |
worse outcomes | 3 |
communal sleeping | 3 |
study identified | 3 |
fold higher | 3 |
became infected | 3 |
lung injury | 3 |
deaths worldwide | 3 |
related coronaviruses | 3 |
past days | 3 |
existing plans | 3 |
higher mean | 3 |
wonder whether | 3 |
histopathologic examination | 3 |
original manuscript | 3 |
influenza season | 3 |
measles vaccination | 3 |
medical association | 3 |
early phase | 3 |
contact tracing | 3 |
protease inhibitor | 3 |
humoral immunity | 3 |
specific groups | 3 |
first line | 3 |
american persons | 3 |
animal studies | 3 |
infection rates | 3 |
chronic disease | 3 |
nasal swabs | 3 |
use cases | 3 |
italian covid | 3 |
coping strategies | 3 |
care team | 3 |
structural inequities | 3 |
two patients | 3 |
structural racism | 3 |
traumatic stress | 3 |
prior year | 3 |
gold standard | 3 |
status among | 3 |
many cases | 3 |
greater risk | 3 |
long term | 3 |
homeless service | 3 |
comparative study | 3 |
unproven interventions | 3 |
sore throat | 3 |
many correctional | 3 |
floor mats | 3 |
strategies aimed | 3 |
disproportionately high | 3 |
rheumatoid arthritis | 3 |
duration data | 3 |
national academies | 3 |
greatest risk | 3 |
influenza among | 3 |
times higher | 3 |
equitable access | 3 |
policy committee | 3 |
direct contact | 3 |
gender identity | 3 |
black patients | 3 |
health issues | 3 |
correctional systems | 3 |
disease progression | 3 |
seeking behaviors | 3 |
patients dying | 3 |
psychiatric morbidity | 3 |
academic internal | 3 |
equity researchers | 3 |
yellow fever | 3 |
current pandemic | 3 |
antiviral activity | 3 |
received high | 3 |
country comparisons | 3 |
adequately powered | 3 |
leaders must | 3 |
new observational | 3 |
clinical decision | 3 |
disease spread | 3 |
related factors | 3 |
increased severity | 3 |
readily available | 3 |
prevent influenza | 3 |
endemic human | 3 |
minority community | 3 |
ecosystem series | 3 |
marital status | 3 |
medical autopsy | 3 |
connecticut health | 3 |
art regimens | 3 |
neutralizing antibody | 3 |
reduction training | 3 |
flow assays | 3 |
promising therapies | 3 |
civil rights | 3 |
surveillance studies | 3 |
common coronavirus | 3 |
receiving antiretroviral | 3 |
first month | 3 |
virus disease | 3 |
per capita | 3 |
health crises | 3 |
stress exposure | 3 |
minority groups | 3 |
hiv clinics | 3 |
patient experience | 3 |
computed tomographic | 3 |
fatality rates | 3 |
forgotten pandemic | 3 |
perceived personal | 3 |
test positivity | 3 |
compound disparate | 3 |
epidemic size | 3 |
viral entry | 3 |
among hospitalized | 3 |
case reports | 3 |
disease mental | 3 |
poorer health | 3 |
first case | 3 |
care organizations | 3 |
deficit approach | 3 |
provide clear | 3 |
patients infected | 3 |
acute stress | 3 |
content key | 3 |
study design | 3 |
suspected covid | 3 |
persons without | 3 |
hospital mortality | 3 |
panel members | 3 |
discuss race | 3 |
acute lung | 3 |
care workforce | 3 |
get seriously | 3 |
existing disparities | 3 |
encounters involved | 3 |
charm network | 3 |
specific concerns | 3 |
seasonal influenza | 3 |
random sample | 3 |
get vaccinated | 3 |
created rapidly | 3 |
care systems | 3 |
addressing moral | 3 |
situation report | 3 |
immune enhancement | 3 |
preexposure prophylaxis | 3 |
current crisis | 3 |
sars transmission | 3 |
pathologic features | 3 |
designed seroepidemiologic | 3 |
massive pulmonary | 3 |
little prepared | 3 |
current status | 3 |
herd protection | 3 |
persons younger | 3 |
less prepared | 3 |
hardest hit | 3 |
already made | 3 |
nationally representative | 3 |
next months | 3 |
outbreak investigation | 3 |
wider racial | 3 |
completion date | 3 |
steering committee | 3 |
serologic correlates | 3 |
controlled study | 3 |
coding team | 3 |
day mortality | 3 |
health information | 3 |
medical treatment | 3 |
sex hormone | 3 |
oxygen saturation | 3 |
family members | 3 |
organ dysfunction | 3 |
minority populations | 3 |
nasal obstruction | 3 |
poor outcomes | 3 |
vaccine acceptance | 3 |
statewide random | 3 |
asked whether | 3 |
among medical | 3 |
cd lymphocytes | 3 |
adjusted prevalence | 3 |
time since | 3 |
influenza epidemic | 3 |
specific attack | 3 |
true number | 3 |
specific risk | 3 |
surveillance system | 3 |
social analysis | 3 |
important confounding | 3 |
evolving needs | 3 |
frontline health | 3 |
term mental | 3 |
will provide | 3 |
among homeless | 3 |
studies will | 3 |
respiratory infections | 3 |
mild case | 3 |
vaccination campaigns | 3 |
developed test | 3 |
coronary artery | 3 |
addressing clinician | 3 |
among older | 3 |
tertiary hospital | 3 |
draw conclusions | 3 |
health metrics | 3 |
conspiracy theories | 3 |
even though | 3 |
frontline clinicians | 3 |
rapid review | 3 |
blood pressure | 3 |
adults aged | 3 |
veterans health | 3 |
patient outcomes | 3 |
critical knowledge | 3 |
will sustain | 3 |
survey items | 3 |
mswolf northwestern | 3 |
health researchers | 3 |
asymptomatic infections | 3 |
serious medical | 3 |
time point | 3 |
task force | 3 |
complete autopsy | 3 |
infected patients | 3 |
tissue samples | 3 |
king county | 3 |
specific igg | 3 |
transmission among | 3 |
patients included | 3 |
histopathologic changes | 3 |
current evidence | 3 |
binomial logistic | 3 |
minimally symptomatic | 3 |
seeking behavior | 3 |
review conducted | 3 |
sometimes surprising | 3 |
hong kong | 3 |
total number | 3 |
attack rates | 3 |
universal coverage | 3 |
stress reactions | 3 |
evidence suggests | 3 |
position papers | 3 |
men aged | 3 |
influenza virus | 3 |
use among | 3 |
shared rooms | 3 |
neutralization assays | 3 |
clinical research | 3 |
prolonged qtc | 3 |
host cells | 3 |
positive test | 3 |
without symptoms | 3 |
congregate settings | 3 |
worsening symptoms | 3 |
might consider | 2 |
quinapril heart | 2 |
emergency department | 2 |
existing public | 2 |
community transmission | 2 |
investigational new | 2 |
statistical significance | 2 |
interquartile range | 2 |
median age | 2 |
study selection | 2 |
veterans hospital | 2 |
health effects | 2 |
world war | 2 |
correctional settings | 2 |
trial investigators | 2 |
respiratory pathogens | 2 |
among individuals | 2 |
arb treatment | 2 |
thereby reducing | 2 |
selection criteria | 2 |
linked immunosorbent | 2 |
densely populated | 2 |
clinical teams | 2 |
will help | 2 |
linear regression | 2 |
personal resilience | 2 |
immune activation | 2 |
cov infection | 2 |
basic protections | 2 |
quality evidence | 2 |
interventions will | 2 |
ventricular arrhythmias | 2 |
college road | 2 |
spread widely | 2 |
subclinical infections | 2 |
address vaccine | 2 |
sex hormones | 2 |
demonstrate heightened | 2 |
ncov cases | 2 |
syndrome outbreak | 2 |
job roles | 2 |
commonwealth fund | 2 |
ethnically diverse | 2 |
bcg vaccination | 2 |
investigating sex | 2 |
support interventions | 2 |
different regions | 2 |
sars among | 2 |
mean duration | 2 |
patient safety | 2 |
longer associated | 2 |
care sites | 2 |
per persons | 2 |
humoral response | 2 |
cardiac pathology | 2 |
immunity will | 2 |
serious covid | 2 |
activation index | 2 |
hiv covid | 2 |
consumer health | 2 |
designated hospital | 2 |
critical first | 2 |
received tdf | 2 |
hospital universitario | 2 |
renal tropism | 2 |
multivariable poisson | 2 |
better health | 2 |
care society | 2 |
holistic patient | 2 |
may facilitate | 2 |
prolonged uncertainty | 2 |
scale isolation | 2 |
care units | 2 |
care staff | 2 |
university medical | 2 |
conflictofinterest forms | 2 |
percentage points | 2 |
disasters underscore | 2 |
among hospital | 2 |
reuters poll | 2 |
specific questions | 2 |
cfr estimates | 2 |
severe coronavirus | 2 |
coronavirus diseases | 2 |
recovery phase | 2 |
implementation response | 2 |
blood vessels | 2 |
clinical concern | 2 |
population benefit | 2 |
ide reverse | 2 |
isolation period | 2 |
york university | 2 |
states determinants | 2 |
histologic findings | 2 |
vaccination intent | 2 |
computer terminal | 2 |
moore foundation | 2 |
severely ill | 2 |
white children | 2 |
reaction assay | 2 |
available sex | 2 |
philadelphia tribune | 2 |
lining cells | 2 |
evidence becomes | 2 |
sentinel surveillance | 2 |
authorization letter | 2 |
previously available | 2 |
article shares | 2 |
gates ventures | 2 |
ace gene | 2 |
officer unions | 2 |
meet evolving | 2 |
without azithromycin | 2 |
risk covid | 2 |
medical products | 2 |
odds ratios | 2 |
identical epidemic | 2 |
reduce disparities | 2 |
interstitial areas | 2 |
collected mid | 2 |
reported smell | 2 |
illness among | 2 |
pneumonia emergency | 2 |
hospitalized patient | 2 |
virus outbreaks | 2 |
clinical context | 2 |
nrti backbone | 2 |
stay home | 2 |
also suggest | 2 |
included infographics | 2 |
general surgery | 2 |
hmdyb hi | 2 |
symptomatic persons | 2 |
act now | 2 |
potential public | 2 |
newest vital | 2 |
elisa test | 2 |
testing outside | 2 |
financial support | 2 |
respondents reported | 2 |
systemic inflammation | 2 |
prior experience | 2 |
common sense | 2 |
higher titers | 2 |
high titers | 2 |
may pose | 2 |
participants reported | 2 |
front lines | 2 |
moral distress | 2 |
cognitive function | 2 |
higher prevalence | 2 |
psychological status | 2 |
poorly described | 2 |
federally qualified | 2 |
one author | 2 |
will eventually | 2 |
examined hospitalization | 2 |
single time | 2 |
days vs | 2 |
hiv hospital | 2 |
related psychiatric | 2 |
differentiating factors | 2 |
rna detected | 2 |
values among | 2 |
accreditation council | 2 |
testing period | 2 |
mean ct | 2 |
nszsf nu | 2 |
determine whether | 2 |
training programs | 2 |
vital surveillances | 2 |
probable bat | 2 |
new orleans | 2 |
mostly middle | 2 |
respiratory disease | 2 |
core outcome | 2 |
vaccine status | 2 |
flu study | 2 |
hkj dm | 2 |
harlem hospital | 2 |
replication intermediates | 2 |
staff worked | 2 |
testing capacity | 2 |
synthesis ecosystem | 2 |
cases detected | 2 |
population prevalence | 2 |
radiologic findings | 2 |
viral neutralization | 2 |
first large | 2 |
antiviral drugs | 2 |
care services | 2 |
covid treatmentguidelines | 2 |
intervention trial | 2 |
corresponding serum | 2 |
right ventricle | 2 |
will vary | 2 |
weak evidence | 2 |
national health | 2 |
threshold values | 2 |
flexner report | 2 |
academic medicine | 2 |
cross reactivity | 2 |
viral spread | 2 |
medical students | 2 |
reporting guidelines | 2 |
among communities | 2 |
diverse health | 2 |
black medical | 2 |
community settings | 2 |
fair comparisons | 2 |
study sites | 2 |
hispanic ethnicity | 2 |
host antibodies | 2 |
acute disease | 2 |
road critical | 2 |
might explain | 2 |
potential risk | 2 |
novel therapeutics | 2 |
medical student | 2 |
verbatim responses | 2 |
high nab | 2 |
good things | 2 |
symptomatic encounters | 2 |
potential therapies | 2 |
th century | 2 |
older persons | 2 |
occasional portal | 2 |
including hypertension | 2 |
american communities | 2 |
icu intensive | 2 |
lung cancer | 2 |
new data | 2 |
prevalence ratio | 2 |
literature review | 2 |
macular degeneration | 2 |
betty moore | 2 |
data regarding | 2 |
coronavirus vaccination | 2 |
significantly lower | 2 |
pandemics demonstrate | 2 |
working group | 2 |
isolation facility | 2 |
frontline nurses | 2 |
findings may | 2 |
incarcerated populations | 2 |
social norms | 2 |
randomized comparative | 2 |
many essential | 2 |
identifying patients | 2 |
regional general | 2 |
gov statement | 2 |
case definition | 2 |
staff ratio | 2 |
identical age | 2 |
residents aged | 2 |
third drug | 2 |
pandemic forms | 2 |
critical illness | 2 |
since symptom | 2 |
retrospective observational | 2 |
outcomes data | 2 |
stuart slavin | 2 |
pcr detected | 2 |
implemented large | 2 |
normal organ | 2 |
combined lung | 2 |
black chicagoans | 2 |
highest risk | 2 |
media coverage | 2 |
universal medication | 2 |
diagnostic testing | 2 |
organizing phase | 2 |
searched history | 2 |
chronic heart | 2 |
every day | 2 |
host neutralizing | 2 |
black nurses | 2 |
proquest historical | 2 |
policy initiatives | 2 |
vaccine coverage | 2 |
medication schedule | 2 |
workers sars | 2 |
tenofovir disoproxil | 2 |
historical context | 2 |
including death | 2 |
attack rate | 2 |
service providers | 2 |
additional shelters | 2 |
pneumonia outbreak | 2 |
test sensitivity | 2 |
failure trial | 2 |
objective olfactory | 2 |
also affect | 2 |
center hamburg | 2 |
connect evidence | 2 |
persons seeking | 2 |
serum levels | 2 |
log pr | 2 |
ethics committee | 2 |
persons older | 2 |
remained similar | 2 |
addressing postpandemic | 2 |
nma project | 2 |
many states | 2 |
greater illness | 2 |
nearly one | 2 |
preliminary evidence | 2 |
artery disease | 2 |
assays cross | 2 |
disoproxil fumarate | 2 |
study investigators | 2 |
literature search | 2 |
deaths reported | 2 |
surveillance study | 2 |
serological test | 2 |
zwe tmq | 2 |
vicarious traumatization | 2 |
biopsy lung | 2 |
medical conditions | 2 |
important role | 2 |
committee subgroup | 2 |
antithrombotic therapy | 2 |
workers lack | 2 |
many evs | 2 |
cochrane risk | 2 |
related morbidity | 2 |
unity studies | 2 |
transmission within | 2 |
coronary arteries | 2 |
white patients | 2 |
ii pneumocyte | 2 |
preliminary report | 2 |
medical vulnerabilities | 2 |
blue buttons | 2 |
sampling device | 2 |
persons compared | 2 |
study prevalence | 2 |
tract infection | 2 |
subunit vaccine | 2 |
providing rapid | 2 |
loved ones | 2 |
better prepared | 2 |
will protect | 2 |
dixie swarm | 2 |
routine opportunities | 2 |
receiving recognition | 2 |
involved persons | 2 |
drug therapy | 2 |
residual confounding | 2 |
immune function | 2 |
rotating staff | 2 |
singapore implemented | 2 |
medical profession | 2 |
clinical care | 2 |
scientific evidence | 2 |
disproportionately affected | 2 |
treating patients | 2 |
hazard ratio | 2 |
inhibitor withdrawal | 2 |
small samples | 2 |
confirmed coronavirus | 2 |
undetectable seroconversion | 2 |
higher ies | 2 |
arrived residents | 2 |
rna polymerase | 2 |
independence mall | 2 |
tract infections | 2 |
subunit vaccines | 2 |
standard indications | 2 |
lower lobes | 2 |
trial preliminary | 2 |
regression model | 2 |
time frame | 2 |
evs employees | 2 |
enter host | 2 |
using real | 2 |
among noninstitutionalized | 2 |
evidence exists | 2 |
health messages | 2 |
epidemiologic studies | 2 |
differential testing | 2 |
selection bias | 2 |
deceased persons | 2 |
disease susceptibility | 2 |
delivering care | 2 |
clinical benefit | 2 |
hospitalization rates | 2 |
analysis reveals | 2 |
found within | 2 |
team members | 2 |
vaccine becomes | 2 |
th floor | 2 |
administration study | 2 |
complex regimens | 2 |
best guess | 2 |
based participatory | 2 |
medical services | 2 |
assistance programs | 2 |
related deaths | 2 |
carrier transmission | 2 |
examining associations | 2 |
rapidly expanding | 2 |
among black | 2 |
slice thickness | 2 |
persistent stress | 2 |
table shows | 2 |
national strategy | 2 |
type angiotensin | 2 |
almost certainly | 2 |
kawasaki disease | 2 |
eua issuance | 2 |
hospital road | 2 |
also detected | 2 |
federal funding | 2 |
vulnerable group | 2 |
shelter i | 2 |
virus transmission | 2 |
shelters serving | 2 |
initial laboratory | 2 |
million darkies | 2 |
prospective studies | 2 |
bronchoalveolar lavage | 2 |
treat immune | 2 |
college degree | 2 |
community spread | 2 |
clinician support | 2 |
bottom panel | 2 |
accepting vaccination | 2 |
health emergencies | 2 |
cd xdl | 2 |
comprehensive clinician | 2 |
among minority | 2 |
consults occurred | 2 |
based application | 2 |
employment status | 2 |
adjunctive therapy | 2 |
vulnerable communities | 2 |
respirator use | 2 |
adaptive covid | 2 |
daily routines | 2 |
green area | 2 |
suggest developing | 2 |
initial review | 2 |
population age | 2 |
sample collection | 2 |
fungal infection | 2 |
robust primary | 2 |
younger ages | 2 |
nontrial access | 2 |
appropriate housing | 2 |
schwartz rounds | 2 |
inform decision | 2 |
external validation | 2 |
findings warrant | 2 |
fact sheet | 2 |
patients older | 2 |
parent study | 2 |
study provides | 2 |
huh cells | 2 |
copies ml | 2 |
disease exacerbations | 2 |
war i | 2 |
european patients | 2 |
clinical data | 2 |
ischemic heart | 2 |
sars infection | 2 |
subscale scores | 2 |
ae galy | 2 |
sure whether | 2 |
additional studies | 2 |
epidemiology team | 2 |
training clinicians | 2 |
estimating age | 2 |
lung biopsy | 2 |
active disease | 2 |
triggering particular | 2 |
shore drive | 2 |
discussion forum | 2 |
encounters occurred | 2 |
live stream | 2 |
pharmacy cabinets | 2 |
physicians envisions | 2 |
pediatric medical | 2 |
spanish hospitals | 2 |
symptom profiles | 2 |
hospital healthcare | 2 |
gov medical | 2 |
reparative changes | 2 |
across countries | 2 |
mediated conditions | 2 |
negative effects | 2 |
presumed asymptomatic | 2 |
mass testing | 2 |
coronaviruses sars | 2 |
chinese population | 2 |
homeless persons | 2 |
common reasons | 2 |
face mask | 2 |
web site | 2 |
research awareness | 2 |
become infected | 2 |
deaths may | 2 |
ophthalmic macular | 2 |
need sufficient | 2 |
stress scales | 2 |
loan repayment | 2 |
contributed equally | 2 |
findings related | 2 |
center services | 2 |
public transit | 2 |
control precautions | 2 |
private room | 2 |
particular responses | 2 |
commentary examines | 2 |
mm hg | 2 |
higher rates | 2 |
individual freedom | 2 |
ftc versus | 2 |
histopathologic findings | 2 |
study eligibility | 2 |
facilitate data | 2 |
greater likelihood | 2 |
school diploma | 2 |
severe symptoms | 2 |
lake shore | 2 |
proposed mechanism | 2 |
converting existing | 2 |
support needs | 2 |
green arrows | 2 |
effective vaccine | 2 |
multivariable adjustment | 2 |
inadequate health | 2 |
asymptomatic carrier | 2 |
tertiary infectious | 2 |
monocyte chemoattractant | 2 |
adverse outcomes | 2 |
states veterans | 2 |
center retrospective | 2 |
lean health | 2 |
correctional facilities | 2 |
psychological resilience | 2 |
places like | 2 |
without hiv | 2 |
will require | 2 |
previously infected | 2 |
risk population | 2 |
sufficient evidence | 2 |
clinical consequences | 2 |
less severe | 2 |
racial segregation | 2 |
prolonged disease | 2 |
serum antibody | 2 |
prioritizing safety | 2 |
longitudinal studies | 2 |
safely outside | 2 |
using routinely | 2 |
provided high | 2 |
data suggest | 2 |
efforts may | 2 |
health officials | 2 |
may play | 2 |
units called | 2 |
rapid systematic | 2 |
chest tube | 2 |
code blue | 2 |
arrows indicate | 2 |
isolation units | 2 |
ncov transmission | 2 |
minority health | 2 |
recent analysis | 2 |
bat origin | 2 |
content appendix | 2 |
health institute | 2 |
hydroxychloroquine sulfate | 2 |
controlled trials | 2 |
care utilization | 2 |
randomized study | 2 |
dleo rpl | 2 |
study also | 2 |
identified new | 2 |
singhealth cluster | 2 |
will die | 2 |
disease patients | 2 |
hospital pharmacies | 2 |
population aged | 2 |
knowledge gaps | 2 |
basic reproduction | 2 |
baltimore sun | 2 |
encounters include | 2 |
inadequate resources | 2 |
metropolitan area | 2 |
white americans | 2 |
anticoagulant treatment | 2 |
indicated hesitancy | 2 |
pneumocyte hyperplasia | 2 |
turbinate nasal | 2 |
effective therapies | 2 |
sample study | 2 |
infection review | 2 |
contact history | 2 |
employee assistance | 2 |
will almost | 2 |
coverage rates | 2 |
respiratory syndromes | 2 |
sign monitoring | 2 |
editorialist discusses | 2 |
health education | 2 |
consistent across | 2 |
ace angiotensin | 2 |
needed now | 2 |
data available | 2 |
michael title | 2 |
text line | 2 |
acei arbs | 2 |
comparability across | 2 |
promote adherence | 2 |
chemoattractant protein | 2 |
randomized intervention | 2 |
acute hospitals | 2 |
rigorous modeling | 2 |
societies worldwide | 2 |
italy included | 2 |
populated small | 2 |
onsite testing | 2 |
also might | 2 |
national hiv | 2 |
health centers | 2 |
participatory research | 2 |
cruise ship | 2 |
psychiatric disorders | 2 |
demonstrated knowledge | 2 |
extrapyramidal disorders | 2 |
may face | 2 |
analysis found | 2 |
alveolar lining | 2 |
dependent rna | 2 |
shared day | 2 |
drug use | 2 |
anxiety among | 2 |
symptoms among | 2 |
asymptomatic cases | 2 |
mechanisms underlying | 2 |
significantly higher | 2 |
care provider | 2 |
also true | 2 |
daily tribune | 2 |
widely available | 2 |
increased susceptibility | 2 |
comorbid cardiovascular | 2 |
results suggest | 2 |
study participants | 2 |
renin angiotensin | 2 |
trial facemasks | 2 |
survey period | 2 |
rapid access | 2 |
press releases | 2 |
undergone complete | 2 |
measures will | 2 |
scores among | 2 |
clinical setting | 2 |
overrepresented among | 2 |
contrast medium | 2 |
lowtiter plasma | 2 |
beats min | 2 |
institutions must | 2 |
disease outcomes | 2 |
show symptoms | 2 |
molecular methods | 2 |
hospital systems | 2 |
days per | 2 |
reported symptom | 2 |
eli lilly | 2 |
nucleotide analogues | 2 |
share ipd | 2 |
smoking status | 2 |
ecological fallacy | 2 |
institutional isolation | 2 |
independent predictors | 2 |
higher burden | 2 |
nucleic acid | 2 |
lessons learned | 2 |
older age | 2 |
antiretroviral drugs | 2 |
epidemic growth | 2 |
wellness needs | 2 |
american proquest | 2 |
chloroquine group | 2 |
services must | 2 |
funding sources | 2 |
current system | 2 |
statistical computing | 2 |
approach rather | 2 |
might become | 2 |
support line | 2 |
induced changes | 2 |
early reports | 2 |
aplastic anemia | 2 |
products exclusively | 2 |
hiv aids | 2 |
coronavirus within | 2 |
previously reported | 2 |
timely adoption | 2 |
provisional death | 2 |
treatment trial | 2 |
care use | 2 |
health efforts | 2 |
key questions | 2 |
ensuring community | 2 |
magna pure | 2 |
qualitative analysis | 2 |
bk bnox | 2 |
hiv preexposure | 2 |
colleagues explored | 2 |
new zealand | 2 |
getting influenza | 2 |
emerging coronaviruses | 2 |
primary outcome | 2 |
study population | 2 |
descriptive study | 2 |
magnifying existing | 2 |
participants days | 2 |
tells us | 2 |
fighting covid | 2 |
efforts will | 2 |
detect sars | 2 |
accounts examining | 2 |
paid sick | 2 |
prevalence estimates | 2 |
yellow asterisks | 2 |
inflammatory status | 2 |
early th | 2 |
disease prevention | 2 |
vaccinated included | 2 |
blue arrows | 2 |
survey completion | 2 |
adverse events | 2 |
hypertension hospitalized | 2 |
adults living | 2 |
disclosure information | 2 |
postmortem findings | 2 |
positive rt | 2 |
levels correlated | 2 |
occult covid | 2 |
sample size | 2 |
similar among | 2 |
news score | 2 |
singapore general | 2 |
scientific medical | 2 |
activities may | 2 |
media download | 2 |
unmet need | 2 |
health mandates | 2 |
published reports | 2 |
care gaps | 2 |
spreads efficiently | 2 |
ambulatory patients | 2 |
workers became | 2 |
conceptual framework | 2 |
vaccinated individuals | 2 |
synthesis model | 2 |
highly conserved | 2 |
sleeping areas | 2 |
ofd ipvs | 2 |
arb exposure | 2 |
potential strategies | 2 |
day center | 2 |
younger age | 2 |
congregate sleeping | 2 |
different types | 2 |
approach may | 2 |
workers low | 2 |
qualified health | 2 |
biological age | 2 |
reproduction number | 2 |
approximately one | 2 |
studies examining | 2 |
red area | 2 |
residential segregation | 2 |
polyclonal antibodies | 2 |
bias tool | 2 |
small numbers | 2 |
public spaces | 2 |
large cohort | 2 |
asymptomatic carriage | 2 |
spanish hiv | 2 |
unique facilities | 2 |
cardiovascular conditions | 2 |
critical structural | 2 |
may reduce | 2 |
specialized training | 2 |
voluntary participation | 2 |
mediated diseases | 2 |
scale institutional | 2 |
human coronavirus | 2 |
lower among | 2 |
nosocomial infections | 2 |
influence therapeutic | 2 |
assay selection | 2 |
coronary heart | 2 |
lower rates | 2 |
patient self | 2 |
last updated | 2 |
also serve | 2 |
racial ethnic | 2 |
track clinician | 2 |
stream throughout | 2 |
positive antibody | 2 |
cumulative incidence | 2 |
line clinicians | 2 |
inflammatory infiltrates | 2 |
rated overall | 2 |
epidemic severity | 2 |
forest plots | 2 |
low dose | 2 |
inhibiting rnadrnap | 2 |
alveolar fibrinous | 2 |
different populations | 2 |
aids plan | 2 |
nutrition examination | 2 |
negative controls | 2 |
viral testing | 2 |
internship early | 2 |
based health | 2 |
dashed black | 2 |
death counts | 2 |
red cross | 2 |
among young | 2 |
previous epidemics | 2 |
illness onset | 2 |
lemeshow statistics | 2 |
per week | 2 |
inadequate ppe | 2 |
themes emerged | 2 |
cumulative infections | 2 |
treat covid | 2 |
mildly symptomatic | 2 |
lower influenza | 2 |
tract symptoms | 2 |
onsite study | 2 |
see end | 2 |
reporting delays | 2 |
key areas | 2 |
new cohort | 2 |
societal infrastructure | 2 |
medical records | 2 |
imminent threat | 2 |
postexposure prophylaxis | 2 |
consistent results | 2 |
historical newspapers | 2 |
prison residents | 2 |
quality control | 2 |
older individuals | 2 |
label non | 2 |
data may | 2 |
mucosal tissues | 2 |
reninangiotensin system | 2 |
higher levels | 2 |
sleeping spaces | 2 |
higher chance | 2 |
becoming infected | 2 |
across assays | 2 |
luto outside | 2 |
integrase inhibitor | 2 |
resources necessary | 2 |
randomised controlled | 2 |
medical practice | 2 |
federal state | 2 |
acute illness | 2 |
predominantly used | 2 |
little worried | 2 |
mean dass | 2 |
negro physician | 2 |
worsening ari | 2 |
hubei province | 2 |
laboratorydeveloped test | 2 |
diseases society | 2 |
nza po | 2 |
national academy | 2 |
important consideration | 2 |
small number | 2 |
health practice | 2 |
initial outbreak | 2 |
prevalence data | 2 |
type ii | 2 |
first step | 2 |
hospital covid | 2 |
icmje conflictofinterest | 2 |
century ago | 2 |
electronic medical | 2 |
outbreak approximately | 2 |
viral positivity | 2 |
nurse vs | 2 |
will use | 2 |
global pandemic | 2 |
hinders assay | 2 |
fever epidemic | 2 |
considered positive | 2 |
risk ratios | 2 |
chloroquine diphosphate | 2 |
corona virus | 2 |
protocolized system | 2 |
inflammatory response | 2 |
ongoing research | 2 |
lilly outside | 2 |
within weeks | 2 |
national plan | 2 |
antigenic targets | 2 |
disproportionate toll | 2 |
biological determinism | 2 |
preferred reporting | 2 |
dried blood | 2 |
stable patients | 2 |
workers involved | 2 |
less serious | 2 |
seattle flu | 2 |
updated information | 2 |
pure roche | 2 |
offer unproven | 2 |
emergency investigational | 2 |
health toll | 2 |
may help | 2 |
will probably | 2 |
highly specific | 2 |
chronic medical | 2 |
pandemic influenza | 2 |
largely indistinguishable | 2 |
data capture | 2 |
soluble angiotensin | 2 |
therapeutics implementation | 2 |
plasma levels | 2 |
research plan | 2 |
registration number | 2 |
respiratory illness | 2 |
life technologies | 2 |
key use | 2 |
abnormal vital | 2 |
pathologic characteristics | 2 |
healthcare research | 2 |
outbreak began | 2 |
wt oyg | 2 |
xu sgguh | 2 |
orders went | 2 |
also may | 2 |
nonpharmaceutical interventions | 2 |
communal space | 2 |
skill set | 2 |
services personnel | 2 |
consecutive covid | 2 |
antimalarial medications | 2 |
pandemic psychological | 2 |
enlarged cervical | 2 |
preexisting pathology | 2 |
size regional | 2 |
infections may | 2 |
house medical | 2 |
adults date | 2 |
thematically analyzed | 2 |
clinical settings | 2 |
treatment decisions | 2 |
workers update | 2 |
integrase inhibitors | 2 |
historical antecedents | 2 |
family shelters | 2 |
damage seems | 2 |
mechanical ventilation | 2 |
outbreak among | 2 |
new drug | 2 |
best available | 2 |
cd cd | 2 |
socioeconomically disadvantaged | 2 |
multiplexed rt | 2 |
fellow clinicians | 2 |
taken together | 2 |
prior pandemics | 2 |
among physicians | 2 |
data collected | 2 |
use authorizations | 2 |
lavage fluid | 2 |
workers risks | 2 |
patients received | 2 |
hospital staff | 2 |
worse covid | 2 |
chicago daily | 2 |
state residents | 2 |
vaccine safety | 2 |
review date | 2 |
asklepios hospital | 2 |
among cases | 2 |
open ended | 2 |
org resources | 2 |
article frames | 2 |
might also | 2 |
treatment remains | 2 |
case count | 2 |
show otherwise | 2 |
national medical | 2 |
fatal cases | 2 |
review annals | 2 |
acei arb | 2 |
solidarity trial | 2 |
thrombus formation | 2 |
see whether | 2 |
excess mortality | 2 |
cases included | 2 |
observational cohort | 2 |
comparator country | 2 |
reactive type | 2 |
effective strategies | 2 |
within hours | 2 |
culturally appropriate | 2 |
sensitive study | 2 |
trusted community | 2 |
plaque reduction | 2 |
lung tissue | 2 |
care coverage | 2 |
also associated | 2 |
hospitalized covid | 2 |
series studies | 2 |
participant encounter | 2 |
relative likelihood | 2 |
tested positive | 2 |
chronic condition | 2 |
participants indicated | 2 |
large rcts | 2 |
hesitant individuals | 2 |
disease pandemic | 2 |
authors thank | 2 |
pharmaceutical interventions | 2 |
lethal covid | 2 |
motivational interviewing | 2 |
influencing factors | 2 |
noninvasive ventilation | 2 |
nonintubated patients | 2 |
prior infection | 2 |
final model | 2 |
south korea | 2 |
study sars | 2 |
ended questions | 2 |
cress umr | 2 |
studies addressing | 2 |
review team | 2 |
work culture | 2 |
routinely collected | 2 |
surgical mask | 2 |
reduce morbidity | 2 |
distress caused | 2 |
mortality due | 2 |
among high | 2 |
coronavirus vaccine | 2 |
ajlf je | 2 |
legal medicine | 2 |
communities may | 2 |
serologic testing | 2 |
identify symptoms | 2 |
hot spots | 2 |
potential harms | 2 |
peripheral blood | 2 |
studies previously | 2 |
coronavirus becomes | 2 |
missing data | 2 |
jek pd | 2 |
based organizations | 2 |
morbidity among | 2 |
community standards | 2 |
community health | 2 |
body fluids | 2 |
younger patients | 2 |
viral clearance | 2 |
heightened distress | 2 |
clinicians may | 2 |
urgently included | 2 |
nab peaked | 2 |
bunk beds | 2 |
frontline medical | 2 |
reporting items | 2 |
thromboembolic events | 2 |
many participants | 2 |
deemed high | 2 |
green space | 2 |
numbered halls | 2 |
postpandemic clinician | 2 |
mild disease | 2 |
city area | 2 |
unprecedented pace | 2 |
nan background | 2 |
related hospitalization | 2 |
questionnaire data | 2 |
monitoring stations | 2 |
medical policy | 2 |
months later | 2 |
known psychological | 2 |
reported symptoms | 2 |
correctional officer | 2 |
identify effective | 2 |
psychological care | 2 |
rna control | 2 |
analysis exists | 2 |
value care | 2 |
treat patients | 2 |
examined whether | 2 |
sex adults | 2 |
second largest | 2 |
services among | 2 |
virus load | 2 |
real time | 2 |
registered rcts | 2 |
protect long | 2 |
outbreak associated | 2 |
disaggregated data | 2 |
security officers | 2 |
start internship | 2 |
reported among | 2 |
higher mortality | 2 |
gov media | 2 |
routine viral | 2 |
key recommendations | 2 |
north lake | 2 |
academies pr | 2 |
neutralization assay | 2 |
substantial proportion | 2 |
undergone minimal | 2 |
unsure whether | 2 |
substantial benefits | 2 |
available assays | 2 |
medium size | 2 |
planned ongoing | 2 |
test implementation | 2 |
healthcare worker | 2 |
kidney disease | 2 |
del amo | 2 |
standard occupational | 2 |
biosafety level | 2 |
resilience intervention | 2 |
provide care | 2 |
nursing staff | 2 |
using sars | 2 |
medical college | 2 |
approximately half | 2 |
coronavirus infections | 2 |
titer group | 2 |
symptom resolution | 2 |
presents unprecedented | 2 |
diseases act | 2 |
clinician workforce | 2 |
national aids | 2 |
crisis text | 2 |
less worried | 2 |
hemodynamic instability | 2 |
yet available | 2 |
serious adverse | 2 |
robust data | 2 |
natural log | 2 |
multinomial logistic | 2 |
path forward | 2 |
china covid | 2 |
provide guidance | 2 |
protecting hospitals | 2 |
term care | 2 |
workers date | 2 |
appropriately designed | 2 |
surrounding communities | 2 |
organization database | 2 |
american community | 2 |
viral titers | 2 |
older men | 2 |
medical workforce | 2 |
sleep quality | 2 |
mild illness | 2 |
biologic plausibility | 2 |
trial chloroquine | 2 |
three studies | 2 |
great outbreak | 2 |
widespread outbreak | 2 |
hivpositive persons | 2 |
among subgroups | 2 |
less intensive | 2 |
heart rate | 2 |
practice guidelines | 2 |
yellow arrow | 2 |
ensuring holistic | 2 |
part ii | 2 |
outcome measure | 2 |
rapid development | 2 |
mall west | 2 |
significantly increased | 2 |
discuss key | 2 |
entire population | 2 |
participating shelters | 2 |
pcr test | 2 |
igg assay | 2 |
reduce crowding | 2 |
population size | 2 |
elected leaders | 2 |
analyses will | 2 |
frontline providers | 2 |
million americans | 2 |
government assistance | 2 |
diagnostic tests | 2 |
showering facilities | 2 |
effective policy | 2 |
hospital survey | 2 |
health policies | 2 |
german federal | 2 |
clinicians working | 2 |
care infrastructure | 2 |
bilateral ground | 2 |
important contributor | 2 |
eua product | 2 |
past decades | 2 |
number pending | 2 |
regarding sars | 2 |
analyses adjusted | 2 |
researchers involved | 2 |
desperately need | 2 |
fibrinous exudates | 2 |
providing access | 2 |
dust settles | 2 |
important questions | 2 |
odds ratio | 2 |
traditional medical | 2 |
data related | 2 |
unadjusted odds | 2 |
food deserts | 2 |
true infection | 2 |
diagnostic test | 2 |
xz gjq | 2 |
housing low | 2 |
surgical residents | 2 |
vf qt | 2 |
smpc reviewed | 2 |
target trial | 2 |
past months | 2 |
crowded dormitories | 2 |
telephone reminders | 2 |
early april | 2 |
receiving abc | 2 |
frontline workers | 2 |
workers living | 2 |
since infection | 2 |
enzyme type | 2 |
health threat | 2 |
examination survey | 2 |
university health | 2 |
olfactory dysfunction | 2 |
direct cause | 2 |
clinical studies | 2 |
health messaging | 2 |
home residents | 2 |